[1]
M. Vrankar, K. Stanic, S. Jelercic, E. Ciric, A. L. Vodusek, and J. But-Hadzic, “Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience”, RO, vol. 55, no. 4, pp. 482–490, Dec. 2021.